Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Propranolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 0.83 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.83 |
| ▸ | NR2E1 | Q9Y466 | 5/20 | 0.83 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.83 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.83 |
| ▸ | HTR2B | P41595 | 3/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.83 |
| ▸ | HTR2A | P28223 | 3/20 | 0.83 |
| ▸ | HTR2C | P28335 | 3/20 | 0.83 |
| ▸ | HTR6 | P50406 | 3/20 | 0.83 |
| ▸ | TSHR | P16473 | 3/20 | 0.83 |
| ▸ | SCN1A | P35498 | 2/20 | 0.83 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.83 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.83 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.83 |
| ▸ | HTR1A | P08908 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propranolol SCHEMBL19177401 | 1.00 | ADRB2 (0.83) | ADRB2ADRB1CYP2D6NR2E1ADRB3 | |
| Propranolol SCHEMBL19177403 | 1.00 | ADRB2 (0.83) | ADRB2ADRB1CYP2D6NR2E1ADRB3 | |
| Levopropranolol SCHEMBL29355940 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6NR2E1ADRB3 | |
| Levopropranolol SCHEMBL3956 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6NR2E1ADRB3 | |
| Dexpropranolol SCHEMBL29577201 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6NR2E1ADRB3 | |
| Propranolol SCHEMBL10537386 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6NR2E1ADRB3 | |
| Propranolol SCHEMBL1561135 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6NR2E1ADRB3 | |
| Propranolol SCHEMBL3955 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6NR2E1ADRB3 | |
| Propranolol SCHEMBL6511347 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6NR2E1ADRB3 | |
| Dexpropranolol SCHEMBL25255 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6NR2E1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087953-B1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX SA (FR) | 2004-11-17 | — | — | EP | disclosed |
| US-20040147575-A1 | Nitrate salts of antihypertensive medicines | NICOX S.A. | 2004-07-29 | — | — | US | disclosed |
| US-6645965-B1 | Sildenafil, hydralazine, minoxidil, or zaprinast; cardiovascular disorders | NICOX S.A. (FR) | 2003-11-11 | — | — | US | disclosed |
| EP-1087953-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999067231-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147575-A1 | Nitrate salts of antihypertensive medicines | NOS2, NOS1, NOS3 | ADRB2 90/4885ADRB1 42/4885CYP2D6 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.